ATE194497T1 - Monoklonale antikoerper gegen lfa-1 zur herstellung eines arzneimittels zur vorbeugung der transplantatabstossung von organen - Google Patents

Monoklonale antikoerper gegen lfa-1 zur herstellung eines arzneimittels zur vorbeugung der transplantatabstossung von organen

Info

Publication number
ATE194497T1
ATE194497T1 AT94905138T AT94905138T ATE194497T1 AT E194497 T1 ATE194497 T1 AT E194497T1 AT 94905138 T AT94905138 T AT 94905138T AT 94905138 T AT94905138 T AT 94905138T AT E194497 T1 ATE194497 T1 AT E194497T1
Authority
AT
Austria
Prior art keywords
organs
producing
monoclonal antibodies
antibodies against
transplant rejection
Prior art date
Application number
AT94905138T
Other languages
English (en)
Inventor
Gilles Alberici
Pierre Caudrelier
Maryvonne Hourmant
Mauff Brigitte Le
Jean-Paul Soulillou
Original Assignee
Imtix Sangstat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9443248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE194497(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imtix Sangstat filed Critical Imtix Sangstat
Application granted granted Critical
Publication of ATE194497T1 publication Critical patent/ATE194497T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT94905138T 1993-01-21 1994-01-21 Monoklonale antikoerper gegen lfa-1 zur herstellung eines arzneimittels zur vorbeugung der transplantatabstossung von organen ATE194497T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9300584A FR2700471B1 (fr) 1993-01-21 1993-01-21 Utilisation d'anticorps monoclonaux anti-LFA-1 pour la préparation d'un médicament destiné à prévenir le rejet des greffes d'organes solides et médicaments obtenus.
PCT/FR1994/000071 WO1994016728A1 (fr) 1993-01-21 1994-01-21 Anticorps monoclonaux anti-lfa-1 pour la preparation d'un medicament destine a prevenir le rejet des greffes d'organes

Publications (1)

Publication Number Publication Date
ATE194497T1 true ATE194497T1 (de) 2000-07-15

Family

ID=9443248

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94905138T ATE194497T1 (de) 1993-01-21 1994-01-21 Monoklonale antikoerper gegen lfa-1 zur herstellung eines arzneimittels zur vorbeugung der transplantatabstossung von organen

Country Status (11)

Country Link
US (1) US6214342B1 (de)
EP (1) EP0680336B1 (de)
JP (1) JPH08505638A (de)
AT (1) ATE194497T1 (de)
AU (1) AU677374B2 (de)
CA (1) CA2154278A1 (de)
DE (1) DE69425246T2 (de)
FR (1) FR2700471B1 (de)
NZ (1) NZ259901A (de)
WO (1) WO1994016728A1 (de)
ZA (1) ZA94446B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
FR2763072B1 (fr) * 1997-05-12 1999-11-05 Pasteur Merieux Serums Vacc Utilisation d'un anticorps monoclonal anti-lfa1 en transplantation renale
US6222832B1 (en) 1998-06-01 2001-04-24 Tantivy Communications, Inc. Fast Acquisition of traffic channels for a highly variable data rate reverse link of a CDMA wireless communication system
US7936728B2 (en) 1997-12-17 2011-05-03 Tantivy Communications, Inc. System and method for maintaining timing of synchronization messages over a reverse link of a CDMA wireless communication system
US8175120B2 (en) 2000-02-07 2012-05-08 Ipr Licensing, Inc. Minimal maintenance link to support synchronization
US7394791B2 (en) * 1997-12-17 2008-07-01 Interdigital Technology Corporation Multi-detection of heartbeat to reduce error probability
US9525923B2 (en) 1997-12-17 2016-12-20 Intel Corporation Multi-detection of heartbeat to reduce error probability
US7496072B2 (en) * 1997-12-17 2009-02-24 Interdigital Technology Corporation System and method for controlling signal strength over a reverse link of a CDMA wireless communication system
US8134980B2 (en) 1998-06-01 2012-03-13 Ipr Licensing, Inc. Transmittal of heartbeat signal at a lower level than heartbeat request
US7221664B2 (en) * 1998-06-01 2007-05-22 Interdigital Technology Corporation Transmittal of heartbeat signal at a lower level than heartbeat request
US7773566B2 (en) 1998-06-01 2010-08-10 Tantivy Communications, Inc. System and method for maintaining timing of synchronization messages over a reverse link of a CDMA wireless communication system
US6867203B2 (en) 1998-12-29 2005-03-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
US6965778B1 (en) * 1999-04-08 2005-11-15 Ipr Licensing, Inc. Maintenance of channel usage in a wireless communication system
WO2001051084A1 (en) * 2000-01-14 2001-07-19 Genentech, Inc. Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1
US8155096B1 (en) 2000-12-01 2012-04-10 Ipr Licensing Inc. Antenna control system and method
US6954448B2 (en) 2001-02-01 2005-10-11 Ipr Licensing, Inc. Alternate channel for carrying selected message types
US7551663B1 (en) 2001-02-01 2009-06-23 Ipr Licensing, Inc. Use of correlation combination to achieve channel detection
CA2867406C (en) 2001-06-13 2016-08-02 Apple Inc. Transmittal of heartbeat signal at a lower level than heartbeat request
US20050266001A1 (en) * 2004-04-02 2005-12-01 Hadley Gregg A Therapeutic blockade of CD103 interactions to prevent clinical renal allograft rejection
EP1735000A2 (de) * 2004-04-16 2006-12-27 Genentech, Inc. Verfahren zur verstärkung des b-zellabbaus
JP6613412B2 (ja) * 2014-04-03 2019-12-04 学校法人獨協学園獨協医科大学 移植免疫応答の抑制方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5762933A (en) * 1987-01-05 1998-06-09 Institut National De La Sante Et De La Recherche Medicale Method for preventing and treating graft failure in a human patient using a monoclonal antibody specific for leucocyte functional antigen LFA-1
US5002869A (en) * 1987-11-02 1991-03-26 Dana-Farber Cancer Institute Monoclonal antibody specific to a novel epitope of the LFA-1 antigen of human T lymphocytes
JP3213314B2 (ja) * 1991-04-05 2001-10-02 ボード・オブ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・ワシントン 幹細胞因子レセプターに対するモノクローナル抗体
AU687755B2 (en) * 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder

Also Published As

Publication number Publication date
NZ259901A (en) 1997-03-24
WO1994016728A1 (fr) 1994-08-04
FR2700471B1 (fr) 1995-04-07
AU677374B2 (en) 1997-04-24
DE69425246D1 (de) 2000-08-17
FR2700471A1 (fr) 1994-07-22
EP0680336A1 (de) 1995-11-08
AU5887694A (en) 1994-08-15
JPH08505638A (ja) 1996-06-18
DE69425246T2 (de) 2001-01-04
EP0680336B1 (de) 2000-07-12
CA2154278A1 (fr) 1994-08-04
ZA94446B (en) 1994-09-01
US6214342B1 (en) 2001-04-10

Similar Documents

Publication Publication Date Title
DE69425246D1 (de) Monoklonale antikoerper gegen lfa-1 zur herstellung eines arzneimittels zur vorbeugung der transplantatabstossung von organen
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
DE69433820D1 (de) Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
ATE180408T1 (de) Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
IS4083A (is) Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja
ATE82495T1 (de) Verfahren zur herstellung pharmazeutischer mischungen.
DE69433013D1 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
ATE135375T1 (de) Glykosaminoglykan-modifiertes protein, verfahren zu dessen herstellung und pharmazeutische zubereitungen, die es enthalten
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
DE69840909D1 (de) Analoge von kokain
DE59303365D1 (de) Derivate in der vitamin d-reihe mit modifikationen in der 20 position, verfahren zu ihrer herstellung, zwischenprodukte für dieses verfahren, diese derivate enthaltende pharmazeutische präparate sowie deren verwendung zur herstellung von arzneimitteln
BE905890A (fr) Anticorps monoclonaux a reaction croisee et protection croisee vis-a-vis des serotypes de p.aeruginosa.
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
DE69232911D1 (de) Verwendung eines polyhydroxybenzamids oder dessen Derivat zur Herstellung eines Medikaments für die Behandlung von viralen Infektionen
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
ATE44156T1 (de) Kovalent gebundener heparin-antithrombin iiikomplex, verfahren zu dessen herstellung und seine verwendung zur behandlung von thrombusembolie.
FI953565A7 (fi) Uusi antikoagulanttikofaktoriaktiivisuus
CA2449488A1 (en) Compositions and methods for treating hyperimmune response in the eye
ATE174798T1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
ATE94764T1 (de) Nasal applizierbares arzneimittel, verfahren zu seiner herstellung und seine verwendung.
UA27048C2 (uk) Лікарський препарат імуhокоригуючої дії hа осhові клітиhhої суспеhзії, спосіб лікуваhhя цукрового діабету з використаhhям цього препарату
ATE201601T1 (de) Pharmazeutische zusammensetzungen enthaltend ein neutralisiertes virus, und verwendung derselben
ATE264112T1 (de) Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
ATE194076T1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen